DSK Co., Ltd
KKRX:1097403,700.00
KRW
-80.00
(-2.12%)
ISIN
KR7109740001
Return %
Stock
S&P 500
1Y
-53.16
14.20
3Y
-26.29
81.12
5Y
-56.62
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 111
- Sector
- Electronic technology
- Industry
- Computer peripherals
- Address
- Ansan-si South Korea
- IPO Date
- Sep 23, 2009
- Website
- dsk.co.kr
- Similar Companies
- Business
- DSK Co., Ltd. is a South Korea-based mechatronics and biopharmaceutical company primarily engaged in the development, manufacturing, and distribution of factory automation equipment for flat panel display and secondary battery manufacturing processes, as well as botulinum toxin-based biotherapeutics. The company operates through two main business divisions: Factory Automation (FA) Equipment and Biotechnology. Its FA Equipment division provides a comprehensive suite of precision manufacturing systems, including display bonding systems such as PCB/FOB (Film-on-Board), TAB/COF (Tape Automated Bonding/Chip-on-Film), and FPC/FOG (Flexible Printed Circuit/Film-on-Glass) bonders; dispensing and inspection systems comprising optical inspection units, silicone dispensers, Ag dotting systems, and auto probe stations; motion control and material handling systems consisting of automated cassette loaders, unloaders, linear robot systems, and direct drive (DD) motors; secondary battery production systems including automated cell assembly, lamination, and notching equipment; and specialized processing units such as atomic layer deposition (ALD) systems for solar cells and UV LED curing systems. Through its biopharmaceutical subsidiary, Protox Co., Ltd., the company develops, manufactures, and commercializes botulinum toxin formulations, antidotes, and biobetter therapeutics under the PROTOXIN brand for aesthetic and clinical indications. DSK Co., Ltd. caters to major flat panel display manufacturers, electric vehicle battery producers, and pharmaceutical distributors across South Korea, China, Europe, and the Americas. Founded in 1995 as Dong Bang Fanics Corporation and renamed DSK Co., Ltd. in 2008, the company is headquartered in Ansan-si, Gyeonggi-do, South Korea. In recent developments, the company broadened its international healthcare footprint as subsidiary Protox received official product approval from the South Korean Ministry of Food and Drug Safety for its botulinum toxin formulation and entered into a 10-year exclusive European distribution agreement with Spanish medical aesthetics company Mesoestetic covering the European Union, the United Kingdom, and Switzerland, adding to its long-term supply partnerships across China, Brazil, and CIS regions, while navigating controlling shareholder restructuring and ownership transition agreements.